Aviptadil
VIP analog for pulmonary conditions; emergency COVID research.
What it is
Aviptadil (RLF-100, Zyesami) is a synthetic version of vasoactive intestinal peptide (VIP), a 28-amino-acid peptide neurotransmitter and hormone with effects on smooth muscle relaxation, vasodilation, and immune modulation. The compound has been studied for various pulmonary and cardiovascular conditions.
Aviptadil received emergency use attention during the COVID-19 pandemic for treatment of respiratory failure, with NeuroRx (now NRx Pharmaceuticals) advancing trials for severe COVID. Results were mixed and the compound did not receive emergency authorization in the US for COVID. It has been used in some compassionate use protocols.
Mechanism of action
VIP receptor activation produces:
- Pulmonary smooth muscle relaxation and bronchodilation
- Vasodilation
- Anti-inflammatory effects
- Possible effects on Type II alveolar cell function
Clinical evidence
Trials in COVID respiratory failure showed mixed results. Earlier research in pulmonary arterial hypertension and acute lung injury has been ongoing for years without producing clear clinical applications.
Why we don’t prescribe it at The Tide
Aviptadil is an experimental cardiopulmonary drug not appropriate for outpatient peptide clinic use. Acute respiratory and cardiovascular emergencies require hospital-level care.
Side effects and contraindications
Hypotension, flushing, GI effects. Not appropriate for our practice setting.